BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

arGEN-X 

Dr Molewaterplein 50

Rotterdam    3015 GE  The Nederlands
Phone: 31-0-10-7038441 Fax: 31-0-10-7038440


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





 Company News
arGEN-X Uses Its Simple Antibody™ Platform To Identify Four "Hotspots" On MET As Targets For Its Therapeutic Antibody Program 4/7/2014 9:23:05 AM    More...
arGEN-X Raises EUR 5 Million From PMV in Extension of EUR 32.5 Million Series B 11/4/2013 9:25:36 AM    More...
arGEN-X and de Duve Institute at the Catholique University of Louvain to Collaborate on Novel Immunomodulation Therapy in Cancer 11/4/2013 9:23:48 AM    More...
arGEN-X Reaches Milestone in Simple Antibody™ Research and Product Development Collaboration With Shire Pharmaceuticals (SHPG) 9/19/2013 10:00:42 AM    More...
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer 9/17/2013 9:05:24 AM    More...
arGEN-X Identifies Potent Antibody Antagonists Against Complex Chronic Pain Target Nav1.7 9/12/2013 9:24:28 AM    More...
arGEN-X Grants Licenses to Its NHance™ Antibody Half-Life Extension Technology 8/6/2013 9:39:06 AM    More...
arGEN-X Advances ARGX-113 Into Preclinical Development for Autoimmune Disorders 4/24/2013 10:02:14 AM    More...
arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology 3/25/2013 9:47:36 AM    More...
arGEN-X Launches NHance(TM) Technology to Generate Better Human Antibody Therapies 3/19/2012 9:05:59 AM    More...
123

//-->